Neutropenia  >>  Pegasys (pegylated interferon α -2a)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pegasys (pegylated interferon α -2a) / Roche
PRINCIPAL, NCT01616524 / 2011-004885-14: Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

Completed
3
880
Japan, US, Europe, RoW
Pegylated interferon lambda (pegIFNλ), BMS-914143, Pegylated interferon alfa-2a (pegIFNα-2a), Pegasys, Ribavirin, Ribasphere, Daclatasvir, BMS-790052, Placebo matching Daclatasvir
Bristol-Myers Squibb
Hepatitis C Virus (HCV)
06/14
09/14
NCT01754974 / 2012-003508-11: Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C

Completed
3
40
Europe, RoW
Peginterferon Lambda-1a, BMS-914143, Ribavirin, Ribasphere, Peginterferon alfa-2a, Pegasys
Bristol-Myers Squibb
Hepatitis C Virus (HCV)
09/14
09/14
2006-006042-33: A pilot, open label, multicenter, randomized clinical trial on Lopinavir/Ritonavir-monotherapy vs Lopinavir/Ritonavir plus selected Nucs, in HIV/HCV coinfected patients with chronic hepatitis C or compensated cirrhosis, starting treatment with Ribavirin and Pegylated Interferon

Ongoing
3
50
Europe
KALETRA, COPEGUS, PEGASYS, KALETRA, COPEGUS, PEGASYS
OSPEDALE S. RAFFAELE
patients affected by HIV and chronic HCV or compensated cirrhosis
 
 
2006-005996-17: A pilot, open label, multicenter, randomized clinical trial on Lopinavir/ritonavir-monotherapy vs Lopinavir/ritonavir plus selected Nucs, in HIV/HCV ARV-naive coinfected patients with chronic hepatitis C or compensated cirrhosis, starting treatment with Ribavirin and Pegylated Interferonﾔ

Ongoing
3
60
Europe
KALETRA, PEGASYS, COPEGUS, KALETRA, PEGASYS, COPEGUS
OSPEDALE S. RAFFAELE
PATIENTS AFFECTED BY HIV/HCV NAIVES FROM THERAPIES
 
 
PIONEER, NCT03833362: Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 ( - Study)

Completed
3
420
RoW
Narlaprevir, Ritonavir, Norvir, Placebo Narlaprevir, Placebo Ritonavir, Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b, Pegasys, PegIntron, Ribavirin, Rebetol
R-Pharm
Hepatitis C
03/16
02/17

Download Options